Table 4.
Agonist relative potencies in PSV in the presence of the EP4 receptor antagonist GW627368X (10 μM) together with comparative data generated at human recombinant EP2 receptors expressed in CHO K1 cells (Wilson et al., 2004)
| Agonist | PSV i.p.o. 10 μM GW627368X | CHO hEP2 |
|---|---|---|
| PGE2 | 1 | 1 |
| PGE1 | 2 | 1 |
| Butaprost FA | 13 | 2 |
| 16,16-dimethyl-PGE2 | 5 | 3 |
| 19-(R)-hydroxy-PGE2 | 8 | 3 |
| 11-deoxy-PGE1 | 16 | 8 |
| GR63799X | 50 | 10 |
| Misoprostol | 13 | 13 |
| BW245C | 16 | |
| PGF2α | 20 | |
| PGD2 | 40 | 25 |
| Butaprost ME | 32 | >30 |
| 17-phenyl-ω-trinor PGE2 | 63 | |
| Iloprost | 2 | >100 |
| Sulprostone | >100 | |
| PGI2 | 32 | ∼320 |
| Cloprostenol | ∼320 | |
| Cicaprost | 16 | >1000 |
| Fluprostenol | >1000 |